-+ 0.00%
-+ 0.00%
-+ 0.00%

Hong Kong Stock Announcement Nuggets | Genting Xinyao: Technology related to the original product Nifukang® is protected by the patent ZL200980127272.5 in China. The patent is currently in effect

Zhitongcaijing·12/30/2025 15:09:03
Listen to the news

Important matters:

Genting Xinyao (01952): Technology related to the original product Nifukang® is protected by the patent ZL200980127272.5 in China. The patent is currently in effect

Liankang Biotechnology Group (00690) reached a strategic cooperation with the National Engineering Research Center of Wenzhou Medical University and the People's Government of Ouhai District, Wenzhou

Hehuang Pharmaceutical (00013) announced that the marketing application for savolitinib (savolitinib) for the treatment of gastric cancer patients with MET amplification in China has been accepted and included in priority review

Fosun Pharmaceutical (02196) Holding Subsidiary's Integrated Nuclear Drug Project SRT-007 Starts Phase I Clinical Trials in China

The absorption and merger of Postbank (01658) and Yuhui Wanjia Bank was approved by the State Financial Supervisory Administration

Minimally Invasive Heart Tong-B (02160): One-year follow-up results of the AltaValveTM Early Feasibility Study Officially Announced

Operating performance:

Xinhuo Technology Holdings (01611) announced annual results, loss attributable to company owners of HK$9.212 million year-on-year profit to loss

Xingqian Development (00640) announced annual results, net profit of approximately HK$122 million, up 21.7% year on year

Zijin Mining (02899) expects net profit of about 51 billion to 52 billion yuan in 2025, an increase of about 59% to 62% over the previous year

Zijin Gold International (02259) Fa Yingxi expects net profit to return to the mother of about US$1.15-1.6 billion in 2025, an increase of about 212%-233% year-on-year